Innovations In Clinical Neuroscience

JAN-FEB 2018

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link:

Contents of this Issue


Page 41 of 53

R E V I E W 42 ICNS Innovations in Clinical Neuroscience • January–February 2018 • Volume 15 • Number 1–2 although the data come from small studies and must be interpreted with caution. 108–111 A recent pilot trial of 15 patients with brain tumor(s) revealed significant post-baseline improvement in attention, graphomotor speed, visual memory, and self-reported quality of life after receiving a daily dose of donepezil for 24 weeks. 111 Lawrence et al 110 reported improved delayed verbal memory following donepezil treatment in patients with breast cancer, with self-reported cognitive impairments 1 to 5 years following adjuvant chemotherapy. Wefel et al 112 reported a delayed time to cognitive decline in patients with brain metastases undergoing WBRT who received memantine treatment compared to placebo. CONCLUSION Cognitive impairment can affect daily functioning, quality of life, and capacity to work in patients with cancer and those in remission. Consequently, cognitive assessment is now an important and necessary part of a comprehensive oncological care plan. Cancer-related cognitive impairment might be due to the direct effects of the cancer itself, nonspecific factors, or comorbid conditions that are independent of the disease and/or due to the adverse effects of the treatment or combination of treatments given for the disease. The prevalence and extent of cognitive impairment associated with cancer is recognized but not well understood due, in part, to marked differences in the research methods and definitions used for evaluating cognitive functioning in these patients. Most studies have identified attention, memory, and information processing as the most frequent cognitive domains impacted by cancer and cancer-related treatments, but further research clearly is needed. Recent efforts have been made to develop common definitions to define cognitive impairment in cancer patients and to suggest guidelines for the most appropriate cognitive tests to be used. Cognitive function has increasingly been recognized as a requisite therapeutic target in many diseases, including cancer. The extent of cognitive impairment that is observed in patients with cancer and those in remission make cognitive functioning a particularly important target for clinical trials and clinical practice in oncology. REFERENCES 1. Weiss B. Chemobrain: a translational challenge for neurotoxicology. Neurotoxicology. 2008;29:891– 898. 2. Hodgson K, Hutchinson A, Wilson C, Nettelbeck T. A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev. 2013;39:297–304. 3. Wefel J, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12:703– 708. 4. Janelsins M, Kesler S, Ahles T, Morrow G. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014;26:102–113. 5. Denlinger C, Ligibel J, Are M, et al. Survivorship: cognitive function, version 1.2014: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2014;12:976–986. 6. Moore H. An overview of chemotherapy-related cognitive dysfunction, or "chemobrain." Oncology (Williston Park). 2014;28:797–804. 7. Jean-Pierre P, Winters P, Ahles T, et al. Prevalence of self-reported memory problems in adult cancer survivors: a national cross-sectional study. J Oncol Pract. 2012;8:30–34. 8. Bradshaw M, Wefel J. The neuropsychology of oncology. In: Parsons M, Hammeke T (eds). Clinical Neuropsychology: A pocket handbook for assessment, Third edition. Washington DC: American Psychological Association;2014:313–337. 9. Wefel J, Patwardhan S, Strange C. Concurrent and criterion validity related evidence for the neurocognitive function clinical trial battery in brain tumor patients. Presented at the 15th Annual Meeting of the Society for Neuro- Oncology; 2010 November 18; Montreal, Quebec. 10. Meyers C, Smith J, Bezjack A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncology. 2004;12:157–165. 11. Gehring K, Aaronson N, Taphoorn M, Sitskoorn M. Interventions for cognitive deficits in patients with a brain tumor: an update. Expert Rev Anticancer Ther. 2010;10:1779–1795. 12. Tucha O, Smely C, Preier M, Lange K. Cognitive deficits before treatment among patients with brain tumors. Neurosurgery. 2000;47:324–333. 13. Klein M, Taphoorn M, Heimans J, et al. Neurobehavioral status and health related quality of life in newly diagnosed high grade glioma patients. J Clin Oncol. 2001;19:4037–4047. 14. van Nieuwenhuizen D, Klein M, Stalpers LJ, et al. Differential effect of surgery and radiotherapy on neurocognitive functioning and health related quality of life in WHO grade I meningioma patients. J Neurooncol. 2007;84:271–278. 15. Aaronson N, Taphoorn M, Heimans J, et al. Compromised health-related quality of life in patients with low-grade glioma. J Clin Oncol. 2011;29:4430–4435. 16. van Loon E, Heijenbrok-Kal M, van Loon W, et al. Assessment methods and prevalence of cognitive dysfunction in patients with low-grade glioma: a systematic review. J Rehabil Med. 2015;47:481– 488. 17. Lageman S, Cerhan J, Locke D, et al. Comparing neuropsychological tasks to optimize brief cognitive batteries for brain tumor clinical trials. J Neurooncol. 2010;96:271–276. 18. Meyers C, Albitar M, Etsey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer. 2005;104:788–793. 19. Ahles T, Saykin A, McDonald B, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat. 2008;110:143–152. 20. Wefel J, Saleeba A, Buzdar A, Meyers C. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;116:3348–3356. 21. Jansen C, Cooper B, Dodd M, Miaskowski C. A prospective longitudinal study of chemotherapy- induced cognitive changes in breast cancer patients. Support Care Cancer. 2011;19:1647– 1656. 22. Wefel J, Vidrine D, Veramonti T, et al. Cognitive impairment in men with testicular cancer prior to adjuvant therapy. Cancer. 2010;117:190–196. 23. Tager F, McKinley P, Schnabel F, et al. The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. Breast Cancer Res Treat. 2010;123:25–34. 24. Walker L, Walker M, Marshall I, et al. Cognitive function in breast cancer patients compared with age matched healthy controls. J Psychopharmacology. 2002;16:A27. 25. Hurria A, Rosen C, Hudis C, et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatric Soc. 2006;54:925–931. 26. Wefel J, Lenzi R, Theriault R, et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004;100:2292–2299. 27. Berman M, Askren M, Jung M, et al. Pretreatment worry and neurocognitive responses in women with breast cancer. Health Psychology. 2014;33:222–231. 28. Hermelink K, Kuchenhoff H, Untch M, et al. Two different sides of 'chemobrain': determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective,

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - JAN-FEB 2018